Stryker is one of the worlds leading medical technology companies and,together with its customers, is driven to make healthcare better. The company offers innovative products and services inOrthopaedics, Medical and Surgical,and Neurotechnology and Spine that help improvepatient and hospital outcomes.

Stryker (NYSE: SYK) announced fourth quarter and full year 2019 financial results and 2020 guidance. For the fourth quarter, net sales reached USD 4.1 Billion an 8.8% increase as organic net sales increased by 8%. For the full year 2019, net sales amounted to USD 14.9 Billion, a 9.4% increase.

We had an excellent finish to 2019, achieving 8.1% full-year organic sales growth and 13% adjusted EPS gains.This marks our seventh consecutive year of accelerating organic sales growth and is a testament to our talent, culture and durable operating model, said Kevin Lobo, Chairman and Chief Executive Officer. The performance was balanced across businesses and geographies and positions us well for continued success.

Net earnings for the fourth quarter and full year reached USD 725 Million and USD 2.1 Billion, falling 64.9% and 41.4%. Net sales growth in 2020 is expected to range from 6.5% to 7.5% while adjusted net earnings per diluted share is expected to range from USD 9.00 to USD 9.20. For the first quarter of 2020, adjusted net earnings per diluted share is anticipated to range from USD 2.05 to USD 2.10.

More here:

Stryker Announces Q4/Full Year 2019 Financial Results and 2020 Outlook - Financialbuzz.com